Keyphrases
Head-and-neck
100%
N719
100%
Overcoming Resistance
100%
Cetuximab
100%
Squamous Cell Carcinoma of Head
100%
PIK3CA
100%
Partial Response
17%
Progressive Disease
13%
Philadelphia
13%
Epidermal Growth Factor Receptor
10%
Best Overall Response
10%
In Cancer
6%
Overall Response Rate
6%
Patient Demographics
6%
Recurrent Metastatic
6%
Mammalian Target of Rapamycin (mTOR)
6%
Metastatic Squamous Cell Carcinoma
6%
Pretreated Patients
6%
Disease Control Rate
6%
Phase Ib Study
6%
Gilbert
3%
Safety Data
3%
Hyperglycemia
3%
Adverse Events
3%
Additive Effect
3%
Antitumor Activity
3%
In Vivo Applications
3%
Direct Therapy
3%
Preclinical Data
3%
Xenograft Model
3%
Once-daily
3%
Complete Response
3%
Stable Disease
3%
Squamous Cell Carcinoma (SqCC)
3%
Efficacy Data
3%
Phosphoinositide 3-kinase (PI3K)
3%
Resistance Mechanisms
3%
Esophageal Squamous Cell Carcinoma
3%
Pathway Activation
3%
Acquired Resistance
3%
Stomatitis
3%
Dermatitis
3%
Response Evaluation Criteria in Solid Tumors (RECIST)
3%
Qing
3%
Tumor Regression
3%
Hanging
3%
Non-progressive
3%
Platinum-based Chemotherapy
3%
Intolerant
3%
Anti-EGFR
3%
Dual Inhibition
3%
Receptor Overexpression
3%
Epidermal Growth Factor Receptor Inhibitors
3%
Inhibitor Activity
3%
PI3K-AKT-mTOR Pathway
3%
Tumor Lysis Syndrome
3%
Munster
3%
PI3K Inhibitor
3%
First-line Regimen
3%
Ther
3%
Intrinsic Resistance
3%
CR Model
3%
Chia
3%
Squamous Cell Tumor
3%
Acneiform
3%
Sheng
3%
Recommended Phase 2 Dose
3%
Cetuximab Resistance
3%
Neck Cell
3%
Platinum Therapy
3%
Medicine and Dentistry
Squamous Cell Carcinoma
100%
Neck
100%
Alpelisib
100%
Cetuximab
100%
Progressive Disease
13%
Disease
10%
Malignant Neoplasm
10%
Epidermal Growth Factor Receptor
10%
Patient Population
6%
Mammalian Target of Rapamycin
6%
Adverse Event
3%
Neoplasm
3%
Hyperglycemia
3%
Arm
3%
Xenograft
3%
Antineoplastic Activity
3%
Cell Line
3%
Esophageal Squamous Cell Carcinoma
3%
Stomatitis
3%
Dermatitis
3%
Tumor Regression
3%
Patient History of Chemotherapy
3%
Ampicillin
3%
Epidermal Growth Factor Receptor Kinase Inhibitor
3%
Squamous Cell
3%
Tumor Lysis Syndrome
3%
PI3K/AKT/mTOR Pathway
3%
Anti-Epidermal Growth Factor Receptor
3%
Pharmacology, Toxicology and Pharmaceutical Science
Squamous Cell Carcinoma
100%
Alpelisib
100%
Cetuximab
100%
Disease
23%
Epidermal Growth Factor Receptor
13%
Malignant Neoplasm
10%
Neoplasm
3%
Adverse Event
3%
Hyperglycemia
3%
Antitumor Activity
3%
Dermatitis
3%
Esophageal Squamous Cell Carcinoma
3%
Stomatitis
3%
Ampicillin
3%
Epidermal Growth Factor Receptor Kinase Inhibitor
3%
Tumor Regression
3%
Patient History of Chemotherapy
3%
Tumor Lysis Syndrome
3%
Chia
3%